Proleukin® (aldesleukin) is indicated for the treatment of adults with
metastatic renal cell carcinoma (mRCC) or metastatic melanoma (mM).
think long™
For a chance at years
—cancer free
An immunotherapy treatment for mRCC or mM that can
provide answers in days for a chance at years—cancer free.†
Complete response rates were 7% in mRCC patients and 6% in mM patients1
2,*,†
Most adverse events are predictable, manageable, and reversible1
Results of treatment are evident as early as 1 month after therapy1,2,*
Learn more at www.proleukin.com
infection with gram positive microorganisms.
Antibiotic prophylaxis with oxacillin, nafcillin,
with a reduced incidence of staphylococcal
infections.
Proleukin administration should be withheld in
patients developing moderate to severe lethargy
or somnolence; continued administration may result
in coma.
Please see full Prescribing Information, including Boxed Warning, on the following pages.
A Nestlé Health Science Company.
and ventricular), angina, myocardial infarction, respiratory
mental status changes.
Proleukin treatment is associated with impaired
neutrophil function (reduced chemotaxis) and with an
increased risk of disseminated infection, including sepsis
and bacterial endocarditis. Consequently, preexisting
bacterial infections should be adequately treated
prior to initiation of Proleukin therapy. Patients with
indwelling central lines are particularly at risk for
Go Short Think Long is a trademark of Prometheus Laboratories Inc.
PROMETHEUS and the Link Design are registered trademarks of Société des Produits Nestlé S.A. Vevey, Switzerland.
Proleukin and the swirl design are registered trademarks of Novartis Vaccines and Diagnostics, Inc.
© 2018 Société des Produits Nestlé S.A. Vevey, Switzerland. All rights reserved. PRO18002 10/18
/www.proleukin.com